oral FGFR inhibitor

Ph. I candidate for solid tumors

opt. from previously disclosed lead

Bioorg. Med. Chem.

Astellas Pharma Inc.

oral FGFR inhibitor - Astellas Pharma Inc.

ontext. ASP5878 (Astellas Pharma Inc.) is an oral pan-FGFR inhibitor. The four FGFRs have emerged as attractive targets for cancer in recent years, and we’ve covered several recently. FGFR3…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: